DDX53 and neoplasm: We focused on CT26 as the model system for this study as it is the most extensively investigated syngeneic mouse tumor models in preclinical studies and has been used to validate most immune checkpoint blockade immunotherapeutics currently in the clinic or in clinical trials, with well over 500 studies in literature.